A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Patients With Primary or Recurrent Pterygium
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2018
Price : $35 *
At a glance
- Drugs CBT 001 (Primary)
- Indications Pterygium
- Focus Therapeutic Use
- Sponsors Cloudbreak therapeutics
- 01 Sep 2018 Status changed from active, no longer recruiting to completed.
- 17 Jul 2018 Planned primary completion date changed from 26 May 2018 to 30 Sep 2018.
- 26 Apr 2018 Planned End Date changed from 1 Feb 2018 to 30 Sep 2018.